Women of childbearing potential and contraception in males and females: FYCOMPA is not recommended in women of childbearing potential not using contraception unless clearly necessary. FYCOMPA may decrease the effectiveness of progestative containing hormonal contraceptives. An additional non-hormonal form of contraception is, therefore recommended (see Precautions and Interactions).
Pregnancy: There are limited amounts of data (less than 300 pregnancy outcomes) from the use of FYCOMPA in pregnant women. Studies in animals did not indicate any teratogenic effects in rats or rabbits, but embryotoxicity was observed in rats at maternally toxic doses (see Pharmacology: Toxicology: Preclinical safety data under Actions). FYCOMPA is not recommended during pregnancy.
Breastfeeding: Studies in lactating rats have shown excretion of FYCOMPA and/or its metabolites in milk (see Pharmacology: Toxicology: Preclinical safety data under Actions). It is not known whether FYCOMPA is excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from FYCOMPA therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Fertility: In the fertility study in rats, prolonged and irregular estrous cycles were observed at high-dose (30 mg/kg) in females; however, these changes did not affect the fertility and early embryonic development. There were no effects on male fertility (see Pharmacology: Toxicology: Preclinical safety data under Actions). The effect of FYCOMPA on human fertility has not been established.